Journal article
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
- Abstract:
-
Background: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h. Methods: To capture both possible outcomes of OXi4503 treatment on cell death, plasma samples for analysis by M30 and M65 ELISAs, which measure different circulating forms of cytokeratin 18 as biomarker...
Expand abstract
Actions
Authors
Bibliographic Details
- Journal:
- British Journal of Cancer
- Volume:
- 106
- Issue:
- 11
- Pages:
- 1766-1771
- Publication date:
- 2012-05-22
- DOI:
- EISSN:
-
1532-1827
- ISSN:
-
0007-0920
- Source identifiers:
-
335181
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:335181
- UUID:
-
uuid:1243d56e-d10c-4a31-bd38-5f0ad1410a4b
- Local pid:
- pubs:335181
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2012
If you are the owner of this record, you can report an update to it here: Report update to this record